menu
    • menu

    Company profile for Zag Bio

    Pfanstiehl, a global leader in the manufacture of cGMP high purity, low endotoxin, low metals (HPLE-LM)TM injectable grade excipients.

    Virtual Booth

    Contact Supplier

    Global Pharma Healthcare: Setting the global benchmark in quality, innovation, and care

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    Phyton is a World Leader in Plant Cell Fermentation Technology and Commercial Manufacturing.

    Virtual Booth

    Contact Supplier

    Farmak works in the development, production and marketing of APIs, Intermediates & Specialties// FDA inspected.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Zag Bio is redefining autoimmune disease treatment by harnessing the thymus to restore immune tolerance. Using a proprietary platform, Zag Bio develops thymus-targeted therapies that engage the body’s natural process of T cell central tolerance. Its bifunctional antibodies deliver self-antigens to specialized thymic cells, teaching developing immune cells to recognize and protect the body’s own tissues. By leveraging thymu...
    Zag Bio is redefining autoimmune disease treatment by harnessing the thymus to restore immune tolerance. Using a proprietary platform, Zag Bio develops thymus-targeted therapies that engage the body’s natural process of T cell central tolerance. Its bifunctional antibodies deliver self-antigens to specialized thymic cells, teaching developing immune cells to recognize and protect the body’s own tissues. By leveraging thymus biology, Zag Bio aims to address autoimmunity at its root—restoring immune balance and transforming treatment for millions of patients.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Zag BioUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    https://zagbio.com/
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://zagbio.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Drugs in Development

    read-more
    read-more
    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Zag Bio™ Launches with $80M to Advance Thymus-targeted Medicines for Autoimmune Diseases

    Details:

    The Series A financing for ZAG-101, an unconjugated antibody targeting Type 1 diabetes, will advance research in this key focus area.


    Lead Product(s): ZAG-101

    Therapeutic Area: Endocrinology Brand Name: Undisclosed

    Study Phase: PreclinicalProduct Type: Antibody, Unconjugated

    Sponsor: T1D Fund | Polaris Partners | Mission BioCapital | AbbVie Ventures | Sanofi Ventures | Regeneron Ventures | Boxer Capital

    Deal Size: $80.0 million Upfront Cash: Undisclosed

    Deal Type: Series A Financing October 28, 2025

    blank

    01

    Zag Bio

    U.S.A
    arrow
    BIO Partnering at JPM
    Not Confirmed

    Zag Bio

    U.S.A
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : ZAG-101

    Therapeutic Area : Endocrinology

    Highest Development Status : Preclinical

    Partner/Sponsor/Collaborator : T1D Fund | Polaris Partners | Mission BioCapital | AbbVie Ventures | Sanofi Ventures | Regeneron Ventures | Boxer Capital

    Deal Size : $80.0 million

    Deal Type : Series A Financing

    DEALS_DEV arrow-down

    Zag Bio™ Launches with $80M to Advance Thymus-targeted Medicines for Autoimmune Diseases

    Details : The Series A financing for ZAG-101, an unconjugated antibody targeting Type 1 diabetes, will advance research in this key focus area.

    Product Name : Undisclosed

    Product Type : Antibody, Unconjugated

    Upfront Cash : Undisclosed

    October 28, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search